iHealthScreen, an artificial intelligence (“AI”)-based health-screening company, has scheduled an exclusive Q&A webinar. CEO Alauddin Bhuiyan will host the event, which is slated for July 11, 2023, at 9 a.m. PDT. During the webinar, Bhuiyan will provide an overview of the company, including how iHealthScreen is disrupting the billion-dollar health screening market; he will also discuss the unique benefits of iHealthScreen’s investment opportunity, which capitalizes on the company’s proprietary AI-driven, health-screening software. According to the announcement, iHealthScreen is one of the first companies in the world to receive CE certification and Australian and UAE health approvals for the screening of age-related macular degeneration (“AMD”), diabetic retinopathy (“DR”) and glaucoma.
To attend the webinar, visit https://ibn.fm/4ZkRd
To view the full press release, visit https://ibn.fm/3O0Ad
About iHealthScreen
iHealthScreen’s integrated, retinal imaging-based system makes it one of the first companies in the world to receive CE certification, Australian and UAE health approvals for AMD, DR and glaucoma screening. The company is gaining international traction with contracts in the United States, European Union, Bangladesh and UAE; the company has also been collaborating with Global Victoria in Australia. For more information, please visit www.StartEngine.com/offering/iHealthScreen.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
